369638-69-7

Basic information

• Product Name: (5-Bromomethyl-pyrazin-2-yl)-carbamic acid tert-butyl ester
• Synonyms: (5-Bromomethyl-pyrazin-2-yl)-carbamic acid tert-butyl ester;5-（bormomethyl）pyrazin-2-ylcarbamate;tert-butyl N-[5-(Bromomethyl)pyrazin-2-yl]carbamate
• CAS NO: 369638-69-7
• Molecular Formula: C₁₀H₁₄BrN₃O₂
• Molecular Weight: 288.14
• Mol File: 369638-69-7.mol
• Article Data: 8

Chemical Properties

• Boiling Point: 324.409 °C at 760 mmHg
• Flash Point: 149.997 °C
• Appearance: /
• Density: 1.482 g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.583
• CAS DataBase Reference: (5-Bromomethyl-pyrazin-2-yl)-carbamic acid tert-butyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: (5-Bromomethyl-pyrazin-2-yl)-carbamic acid tert-butyl ester(369638-69-7)
• EPA Substance Registry System: (5-Bromomethyl-pyrazin-2-yl)-carbamic acid tert-butyl ester(369638-69-7)

Safety Data

• Hazardous Substances Data: 369638-69-7(Hazardous Substances Data)

Usage

General Description

The chemical compound "(5-Bromomethyl-pyrazin-2-yl)-carbamic acid tert-butyl ester" is an ester derivative of carbamic acid and contains a pyrazinyl group with a bromomethyl substituent. (5-Bromomethyl-pyrazin-2-yl)-carbamic acid tert-butyl ester is commonly used as a building block in organic synthesis and drug development. It is known for its potential pharmaceutical applications and has been studied for its antimicrobial and pesticidal properties. Its tert-butyl ester functional group makes it more stable and readily accessible for various chemical reactions. (5-Bromomethyl-pyrazin-2-yl)-carbamic acid tert-butyl ester has the potential to be utilized in the development of new drug molecules and agrochemicals due to its unique structure and pharmacological properties.

InChI:InChI=1/C10H14BrN3O2/c1-10(2,3)16-9(15)14-8-6-12-7(4-11)5-13-8/h5-6H,4H2,1-3H3,(H,13,14,15)

Upstream product

• 369638-68-6 tert-butyl (5-methylpyrazin-2-yl)carbamate 
• 5521-55-1 2-methylpyrazin-5-carboxylic acid 

Downstream Products

• 710322-47-7 tert-butyl 5-(cyanomethyl)pyrazin-2-ylcarbamate 
• 1610666-99-3 tert-butyl (5-(((4-cyanophenyl)(methyl)amino)methyl)pyrazin-2-yl)carbamate 
• 1610667-01-0 4-((imidazo[1,2-a]pyrazin-6-ylmethyl)(methyl)amino)benzonitrile 
• 1610667-00-9 4-(((5-aminopyrazin-2-yl)methyl)(methyl)amino)benzonitrile 
• 1610667-02-1 4-(((3-bromoimidazo[1,2-a]pyrazin-6-yl)methyl)(methyl)amino)benzonitrile 
• 1610669-52-7 4-[methyl({3-[4-(trifluoromethyl)phenyl]imidazo[1.2-a]pyrazin-6-yl}methyl)amino]benzonitrile 
• 1380646-54-7 acetic acid 5-[3-(3-fluorophenyl)-2-(4-methanesulfonylphenyl)-propionylamino]-pyrazin-2-ylmethyl ester 
• 1380646-32-1 (S)-3-(4-Fluoro-phenyl)-N-(5-hydroxymethyl-pyrazin-2-yl)-2-(4-methanesulfonyl-phenyl)-propionamide 
• 1380646-31-0 (R)-3-(4-Fluoro-phenyl)-N-(5-hydroxymethyl-pyrazin-2-yl)-2-(4-methanesulfonyl-phenyl)-propionamide 
• 1380646-25-2 acetic acid 5-[3-(4-fluoro-phenyl)-2-(4-methanesulfonyl-phenyl)-propionylamino]-pyrazin-2-ylmethyl ester 
• 1380646-02-5 3-(3-Fluoro-phenyl)-N-(5-hydroxymethyl-pyrazin-2-yl)-2-(4-methanesulfonyl-phenyl)-propionamide 
• 1380645-99-7 3-(4-Fluoro-phenyl)-2-(4-methanesulfonyl-phenyl)-N-(5-{[(2-methoxy-ethyl)-methyl-amino]-methyl}-pyrazin-2-yl)-propionamide 
• 1380645-97-5 3-(4-Fluoro-phenyl)-2-(4-methanesulfonyl-phenyl)-N-(5-methoxymethyl-pyrazin-2-yl)-propionamide 
• 1360055-35-1 6-tert-butyl-2-{3-[5-(5-(cyclobutylaminomethyl)pyrazin-2-ylamino)-1-methyl-6-oxo-1,6-dihydropyridazin-3-yl]-2-(hydroxymethyl)phenyl}-8-fluoro-2H-phthalazin-1-one 

Relevant articles and documents

Aminoheteroaryl benzamides as kinase inhibitors

The present invention provides a compound of Formula (I) or a salt thereof; and therapeutic uses of these compounds. The present invention further provides pharmaceutical compositions comprising these compounds, and compositions comprising these compounds with a therapeutic co-agent.

TYPE II RAF KINASE INHIBITORS

The present invention relates to novel compounds which are able to modulate b-raf kinases, and the use of such compounds in the treatment of various diseases, disorders or conditions.

SELECTIVE INHIBITORS AGAINST Cdk4 AND Cdk6 HAVING AMINOTHIAZOLE SKELETON

The present invention relates to a compound represented by Formula [I]: wherein X is O, S, NH or CH 2 ; Y 1 , Y 2 , Y 3 , Y 4 and Y 5 , which may be identical or different, are each CH or N; however, at least one of Y 1 , Y 2 , Y 3 , Y 4 and Y 5 is N; Z 1 and Z 2 , which may be identical or different, are each CH or N; n is an integer from 1 to 3; R 1 is a C 3 -C 8 cycloalkyl group, a C 6 -C 10 aryl group, an aliphatic heterocyclic ring or an aromatic heterocyclic ring, or a bicyclic aliphatic saturated hydrocarbon group; R 2 and R 3 , which may be identical or different, are each a hydrogen atom, a lower alkyl group, a lower alkenyl group, a C 3 -C 8 cycloalkyl group, a C 6 -C 10 aryl group, an aromatic heterocyclic ring, or the like; and R 4 is a hydrogen atom, a lower alkyl group, a C 3 -C 6 cycloalkyl group or the like, or a pharmaceutically acceptable salt or ester thereof, and a selective inhibitor against Cdk4 and/or Cdk6 or an anticancer agent containing the compound or a pharmaceutically acceptable salt or ester thereof.